Abstract: Primary female genital tract malignant melanoma (PFGMM) is a rare mucosal malignant melanoma with poor prognosis. Surgery has remained the first-line therapeutic option for early-stage PFGMM, but the treatment for patient with advanced or recurrent disease is challenging. Currently, systemic chemotherapy is widely adopted. However, it shows limited effect. New targeted therapy and immunotherapy are worth exploring. Notably, the development and progression of melanoma may correlate with c-kit gene alterations with a mutation rate of about 18.5% for PFGMM. Therefore, c-kit gene is expected to become a new target. In this article, we briefly reviewed the role of c-kit in the occurrence, development, treatment and prognosis of PFGMM.

Key words: Primary female genital tract malignant melanoma (PFGMM), c-kit, Targeted therapy